Class II HDAC Inhibition Hampers Hepatic Stellate Cell Activation by Induction of MicroRNA-29

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Mannaerts, Inge ^a   Eysackers, Nathalie ^a   Onyema, Oscar O ^a   van Beneden, Katrien ^a   Valente, Sergio ^b   Mai, Antonello ^b   Odenthal, Margarete ^c   van Grunsven, Leo A ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 [4 [3 (3 FLUOROPHENYL) 3 OXO 1 PROPENYL] 1 METHYL 1H PYRROL 2 YL]ACRYLOHYDROXAMIC ACID; ALANINE AMINOTRANSFERASE; ALPHA SMOOTH MUSCLE ACTIN; ASPARTATE AMINOTRANSFERASE; CARBON TETRACHLORIDE; COLLAGEN; HISTONE DEACETYLASE 2; MICRORNA 29; PLACEBO; PROTEIN LYSINE 6 OXIDASE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CELL ACTIVATION; CELL DIFFERENTIATION; CELL ISOLATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; GENE EXPRESSION REGULATION; HDAC CLASS 2 GENE; IN VIVO STUDY; LIVER FIBROSIS; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHARMACOLOGICAL BLOCKING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN RNA BINDING; PROTEIN SECRETION; STELLATE CELL; UPREGULATION;

ANIMALS; CARBON TETRACHLORIDE; DISEASE MODELS, ANIMAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; HEPATIC STELLATE CELLS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HYDROXAMIC ACIDS; LIVER; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; MICE; MICRORNAS; PYRROLES; RNA INTERFERENCE;

EID: 84873122711     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055786     Document Type: Article

References (58)

1. Iwaisako K, Brenner DA, Kisseleva T, (2012) What's new in liver fibrosis? The origin of myofibroblasts in liver fibrosis. J Gastroenterol Hepatol 27 (Suppl 2) (): 65-68.
2. Friedman SL, (2008) Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver. Physiol Rev 88: 125-172.
3. Geerts A, (2001) History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. Semin Liver Dis 21: 311-335.
4. Blaner WS, O'Byrne SM, Wongsiriroj N, Kluwe J, D'Ambrosio DM, et al. (2009) Hepatic stellate cell lipid droplets: a specialized lipid droplet for retinoid storage. Biochim Biophys Acta 1791: 467-473.
5. De Minicis S, Seki E, Uchinami H, Kluwe J, Zhang Y, et al. (2007) Gene expression profiles during hepatic stellate cell activation in culture and in vivo. Gastroenterology 132: 1937-1946.
6. Fallowfield JA, (2011) Therapeutic targets in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 300: G709-715.
7. Poelstra K, Schuppan D, (2011) Targeted therapy of liver fibrosis/cirrhosis and its complications. J Hepatol 55: 726-728.
8. Guo CJ, Pan Q, Cheng T, Jiang B, Chen GY, et al. (2009) Changes in microRNAs associated with hepatic stellate cell activation status identify signaling pathways. FEBS J 276: 5163-5176.
9. Ji J, Zhang J, Huang G, Qian J, Wang X, et al. (2009) Over-expressed microRNA-27a and 27b influence fat accumulation and cell proliferation during rat hepatic stellate cell activation. FEBS Lett 583: 759-766.
10. Bartel DP, (2009) MicroRNAs: target recognition and regulatory functions. Cell 136: 215-233.
11. Roderburg C, Urban GW, Bettermann K, Vucur M, Zimmermann H, et al. (2011) Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology 53: 209-218.
12. Kwiecinski M, Noetel A, Elfimova N, Trebicka J, Schievenbusch S, et al. (2011) Hepatocyte growth factor (HGF) inhibits collagen I and IV synthesis in hepatic stellate cells by miRNA-29 induction. PLoS ONE 6: e24568.
13. Noetel A, Kwiecinski M, Elfimova N, Huang J, Odenthal M, (2012) microRNA are Central Players in Anti- and Profibrotic Gene Regulation during Liver Fibrosis. Front Physiol 3: 49.
14. Mann J, Oakley F, Akiboye F, Elsharkawy A, Thorne AW, et al. (2007) Regulation of myofibroblast transdifferentiation by DNA methylation and MeCP2: implications for wound healing and fibrogenesis. Cell Death Differ 14: 275-285.
15. Niki T, Rombouts K, De Bleser P, De Smet K, Rogiers V, et al. (1999) A histone deacetylase inhibitor, trichostatin A, suppresses myofibroblastic differentiation of rat hepatic stellate cells in primary culture. Hepatology 29: 858-867.
16. Rombouts K, Knittel T, Machesky L, Braet F, Wielant A, et al. (2002) Actin filament formation, reorganization and migration are impaired in hepatic stellate cells under influence of trichostatin A, a histone deacetylase inhibitor. Journal of Hepatology 37: 788-796.
17. Rombouts K, Niki T, Wielant A, Hellemans K, Geerts A, (2001) Trichostatin A, lead compound for development of antifibrogenic drugs. Acta Gastroenterol Belg 64: 239-246.
18. Mannaerts I, Nuytten NR, Rogiers V, Vanderkerken K, van Grunsven LA, et al. (2010) Chronic administration of valproic acid inhibits activation of mouse hepatic stellate cells in vitro and in vivo. Hepatology 51: 603-614.
19. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB, (2003) Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 370: 737-749.
20. Gao YS, Hubbert CC, Lu J, Lee YS, Lee JY, et al. (2007) Histone deacetylase 6 regulates growth factor-induced actin remodeling and endocytosis. Mol Cell Biol 27: 8637-8647.
21. Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, et al. (2002) HDAC6 is a microtubule-associated deacetylase. Nature 417: 455-458.
22. Zhang Y, Li N, Caron C, Matthias G, Hess D, et al. (2003) HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. Embo J 22: 1168-1179.
23. Mai A, Massa S, Pezzi R, Simeoni S, Rotili D, et al. (2005) Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides. J Med Chem 48: 3344-3353.
24. Nebbioso A, Manzo F, Miceli M, Conte M, Manente L, et al. (2009) Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes. EMBO Rep 10: 776-782.
25. Scognamiglio A, Nebbioso A, Manzo F, Valente S, Mai A, et al. (2008) HDAC-class II specific inhibition involves HDAC proteasome-dependent degradation mediated by RANBP2. Biochimica et Biophysica Acta (BBA)- Molecular Cell Research 1783: 2030-2038.
26. Nebbioso A, Dell'aversana C, Bugge AK, Sarno R, Valente S, et al. (2010) HDACs class II selective inhibition alters nuclear receptor dependent differentiation. J Mol Endocrinol 45: 219-228.
27. Naldi M, Calonghi N, Masotti L, Parolin C, Valente S, et al. (2009) Histone post-translational modifications by HPLC-ESI-MS after HT29 cell treatment with histone deacetylase inhibitors. PROTEOMICS 9: 5437-5445.
28. Borbone E, Berlingieri MT, De Bellis F, Nebbioso A, Chiappetta G, et al. (2010) Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation. Oncogene 29: 105-116.
29. Guimaraes EL, Empsen C, Geerts A, van Grunsven LA, (2010) Advanced glycation end products induce production of reactive oxygen species via the activation of NADPH oxidase in murine hepatic stellate cells. J Hepatol 52: 389-397.
30. Andersen CL, Jensen JL, Orntoft TF, (2004) Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res 64: 5245-5250.
31. Pfaffl MW, Tichopad A, Prgomet C, Neuvians TP, (2004) Determination of stable housekeeping genes, differentially regulated target genes and sample integrity: BestKeeper-Excel-based tool using pair-wise correlations. Biotechnol Lett 26: 509-515.
32. Colussi C, Rosati J, Straino S, Spallotta F, Berni R, et al. (2011) Nε-lysine acetylation determines dissociation from GAP junctions and lateralization of connexin 43 in normal and dystrophic heart. Proceedings of the National Academy of Sciences 108: 2795-2800.
33. Lenoir O, Flosseau K, Ma FX, Blondeau B, Mai A, et al. (2011) Specific control of pancreatic endocrine beta- and delta-cell mass by class IIa histone deacetylases HDAC4, HDAC5, and HDAC9. Diabetes 60: 2861-2871.
34. Bulow R, Fitzner B, Sparmann G, Emmrich J, Liebe S, et al. (2007) Antifibrogenic effects of histone deacetylase inhibitors on pancreatic stellate cells. Biochem Pharmacol 74: 1747-1757.
35. Kee HJ, Kook H, (2011) Roles and targets of class I and IIa histone deacetylases in cardiac hypertrophy. J Biomed Biotechnol 2011: 928326.
36. Pang M, Zhuang S, (2010) Histone Deacetylase: A Potential Therapeutic Target for Fibrotic Disorders. Journal of Pharmacology and Experimental Therapeutics 335: 266-272.
37. Van Beneden K, Geers C, Pauwels M, Mannaerts I, Verbeelen D, et al. (2011) Valproic acid attenuates proteinuria and kidney injury. J Am Soc Nephrol 22: 1863-1875.
38. Ogawa T, Iizuka M, Sekiya Y, Yoshizato K, Ikeda K, et al. (2009) Suppression of type I collagen production by microRNA-29b in cultured human stellate cells. Biochemical and Biophysical Research Communications 391: 316-321.
39. Bush EW, McKinsey TA, (2009) Protein Acetylation in the Cardiorenal Axis: The Promise of Histone Deacetylase Inhibitors. Circ Res 106: 272-284.
40. Richon VM, Sandhoff TW, Rifkind RA, Marks PA, (2000) Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proceedings of the National Academy of Sciences 97: 10014-10019.
41. Lavelle D, Chen Y-H, Hankewych M, DeSimone J, (2001) Histone deacetylase inhibitors increase p21WAF1 and induce apoptosis of human myeloma cell lines independent of decreased IL-6 receptor expression. American Journal of Hematology 68: 170-178.
42. Georges PC, Hui JJ, Gombos Z, McCormick ME, Wang AY, et al. (2007) Increased stiffness of the rat liver precedes matrix deposition: implications for fibrosis. Am J Physiol Gastrointest Liver Physiol 293: G1147-1154.
43. Olsen AL, Bloomer SA, Chan EP, Gaca MDA, Georges PC, et al. (2011) Hepatic Stellate Cells Require a Stiff Environment for Myofibroblastic Differentiation. American Journal of Physiology- Gastrointestinal and Liver Physiology.
44. Glenisson W, Castronovo V, Waltregny D, (2007) Histone deacetylase 4 is required for TGFbeta1-induced myofibroblastic differentiation. Biochim Biophys Acta 1773: 1572-1582.
45. Guo W, Shan B, Klingsberg RC, Qin X, Lasky JA, (2009) Abrogation of TGF-beta1-induced fibroblast-myofibroblast differentiation by histone deacetylase inhibition. Am J Physiol Lung Cell Mol Physiol 297: L864-870.
46. Qin L, Han YP, (2010) Epigenetic Repression of Matrix Metalloproteinases in Myofibroblastic Hepatic Stellate Cells through Histone Deacetylases 4. Implication in Tissue Fibrosis. Am J Pathol 177: 1915-1928.
47. Wendtner CM, (2012) Cocktail of eternity: HDAC meets miR. Blood 119: 1095-1096.
48. Sampath D, Liu C, Vasan K, Sulda M, Puduvalli VK, et al. (2012) Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia. Blood 119: 1162-1172.
49. Du SL, Pan H, Lu WY, Wang J, Wu J, et al. (2007) Cyclic Arg-Gly-Asp peptide-labeled liposomes for targeting drug therapy of hepatic fibrosis in rats. J Pharmacol Exp Ther 322: 560-568.
50. Li F, Li QH, Wang JY, Zhan CY, Xie C, et al. (2012) Effects of interferon-gamma liposomes targeted to platelet-derived growth factor receptor-beta on hepatic fibrosis in rats. J Control Release 159: 261-270.
51. Haughton EL, Tucker SJ, Marek CJ, Durward E, Leel V, et al. (2006) Pregnane X receptor activators inhibit human hepatic stellate cell transdifferentiation in vitro. Gastroenterology 131: 194-209.
52. Horie S, Kitamura Y, Kawasaki H, Terada T, (2000) Inhibitory effects of antisense oligonucleotides on the expression of procollagen type III gene in mouse hepatic stellate cells transformed by simian virus 40doi:10.1046/j.1440-1827.2000.01146.x. Pathology International 50: 937-944.
53. Kordes C, Sawitza I, Häussinger D, (2008) Canonical Wnt signaling maintains the quiescent stage of hepatic stellate cells. Biochemical and Biophysical Research Communications 367: 116-123.
54. Bechmann LP, Zahn D, Gieseler RK, Fingas CD, Marquitan G, et al. (2009) Resveratrol amplifies profibrogenic effects of free fatty acids on human hepatic stellate cells. Hepatology Research 396: 601-608.
55. Liu X, Wang W, Hu H, Tang N, Zhang C, et al. (2006) Smad3 Specific Inhibitor, Naringenin, Decreases the Expression of Extracellular Matrix Induced by TGF-β1 in Cultured Rat Hepatic Stellate Cells. Pharmaceutical Research 23: 82-89.
56. Popov Y, Patsenker E, Bauer M, Niedobitek E, Schulze-Krebs A, et al. (2006) Halofuginone induces matrix metalloproteinases in rat hepatic stellate cells via activation of p38 and NFkappaB. J Biol Chem 281: 15090-15098.
57. Shi YF, Zhang Q, Cheung PY, Shi L, Fong CC, et al. (2006) Effects of rhDecorin on TGF-beta1 induced human hepatic stellate cells LX-2 activation. Biochim Biophys Acta 1760: 1587-1595.
58. Xiao F, Yu K, Dong F, Liang Y, Jun C, et al. (2009) The GABA(B) Receptor Inhibits Activation of Hepatic Stellate Cells. Dig Dis Sci 55: 261-267.